Compare GENC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENC | TLSA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.2M | 155.2M |
| IPO Year | 1995 | 2017 |
| Metric | GENC | TLSA |
|---|---|---|
| Price | $14.53 | $1.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 24.8K | ★ 100.8K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.08 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $8.32 | N/A |
| P/E Ratio | $63.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.80 | $0.73 |
| 52 Week High | $17.40 | $2.60 |
| Indicator | GENC | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 41.88 |
| Support Level | $13.56 | N/A |
| Resistance Level | $14.68 | $1.61 |
| Average True Range (ATR) | 0.54 | 0.11 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 25.09 | 20.27 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.